The PACS Group, Inc. (NYSE: PACS) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, along with AI-powered summaries to help interpret them. As a healthcare holding company in the post-acute care and medical care facilities space, PACS uses SEC reports to describe its facility portfolio, credit arrangements, governance, and risk profile.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q for detailed discussions of PACS Group’s operations, financial condition, and risk factors. These filings also provide context on the company’s role as a holding company, the structure of its independent operating subsidiaries, and the separation between licensed healthcare providers and non-provider entities. AI-generated highlights can point out key sections on post-acute care operations, use of credit facilities, and lease obligations.
Current reports on Form 8-K are particularly important for PACS, given its history of restatements, credit agreement amendments, and NYSE listing updates. Recent 8-K filings have addressed topics such as forbearance and amendments under the company’s amended and restated credit agreement, events of default and related waivers, NYSE listing extensions tied to delayed SEC filings, and the completion of an independent Audit Committee investigation and related restatements. AI summaries can help users quickly understand the implications of these events.
Users can also access proxy materials such as the Definitive Proxy Statement on Schedule 14A, which outlines matters presented to stockholders at the annual meeting, including director elections, auditor ratification, and advisory votes on executive compensation. In addition, the filings page provides real-time updates from EDGAR and convenient access to other forms, such as notifications of late filings on Form 12b-25. Together, these documents offer a comprehensive view of PACS Group’s regulatory history, governance decisions, and financial reporting, with AI tools available to simplify and explain complex disclosures.
PACS affiliate Mark Hancock reported sales totaling 500,000 shares of Common Stock in multiple transactions during June 2026. The filing lists five dispositions dated 06/15/2026 through 06/26/2026 with aggregate proceeds of $18,875,341.54.
The record shows these shares were part of the holdings tied to formation (listed as 54,626,199 shares acquired at formation) but that figure is presented as an issuer/balance item. The schedule is a regulatory notice of proposed or recent sales by an affiliate; the filing does not state any intended use of proceeds or whether transactions were pursuant to a trading plan.
PACS Group, Inc. director and executive vice chair Mark Hancock reported open-market sales of a total of 200,000 shares of common stock. The trades occurred on June 25 and 26, 2026 at weighted average prices around $40–$41 per share.
The filing shows Hancock continues to hold more than 54 million shares of PACS Group common stock directly after these transactions. According to a footnote, the June 2026 sales were effected under a pre‑arranged Rule 10b5-1 trading plan adopted on March 11, 2026, indicating they were scheduled in advance rather than timed discretionarily.
PACS Group, Inc. Chief Accounting Officer Michelle Renee Lewis sold 15,000 shares of common stock in an open-market transaction at a weighted average price of about $40.0119 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading plan, and she continues to hold 370,338 shares directly.
Mark Hancock sold Common stock reported on a Form 144. The filing lists multiple open-market dispositions: 153,254 shares on 06/15/2026 for $5,568,759.95, 63,680 shares on 06/17/2026 for $2,248,413.44, 83,066 shares on 06/16/2026 for $2,982,385.05, and 138,069 shares on 06/25/2026 for $5,567,701.46.
The record also shows 54,626,199 shares were "acquired at formation of the issuer" on 03/01/2023. The transactions are presented as sales with gross proceeds shown next to each trade date.
PACS reported insider sales by Mark Hancock via a Form 144 filing: 153,254 shares sold on 06/15/2026, 83,066 shares sold on 06/16/2026, and 63,680 shares sold on 06/17/2026. The transactions are listed as Common stock dispositions with cash consideration.
PACS submitted a Form 144 notice listing proposed sales of Common Stock through J.P. Morgan Securities LLC. The filing lists a proposed sale quantity of 45,000 shares, a beneficially held figure of 1,748,250 shares, and a total share count of 158,272,376 with an effective date of 06/25/2026. The notice also identifies RSU vesting-related shares of 31,616 (04/15/2026) and 13,384 (04/15/2025) shown as compensation.
PACS Group, Inc. director and executive vice chair Mark Hancock reported two open-market sales of common stock on June 17, 2026 totaling 63,680 shares. The shares were sold at weighted average prices of $35.2838 and $35.7491 per share under a pre-arranged Rule 10b5-1 trading plan adopted on March 11, 2026. After these transactions, Hancock directly holds about 54.3 million shares of PACS Group common stock.
PACS filing a Form 144 reporting proposed sales by an insider. The filing lists two sale notices by Mark Hancock totaling 236,320 shares sold on 06/15/2026 ($5,568,759.95) and 06/16/2026 ($2,982,385.05), respectively. The record shows securities originally acquired at formation on 03/01/2023 and an aggregate holding line of 54,626,199 shares as of 03/01/2023. The broker-dealer listed is Citigroup Global Markets Inc on the NYSE.
PACS Group, Inc. director and co-founder Mark Hancock reported open-market sales of company common stock. Across four transactions on June 15–16, 2026, he sold a total of 236,320 shares, including 83,066 shares at a weighted average price of $35.9038 per share and 134,093 shares at $36.2341 per share.
The filing states these sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 11, 2026, indicating they were scheduled in advance. After these transactions, Hancock directly owned 54,366,277 shares of PACS Group common stock.
Mark Hancock reports a Rule 144 sale of 153,254 shares of Common Stock. The filing records a trade date of 06/15/2026 and proceeds of $5,568,759.95. The notice names Citigroup Global Markets Inc and also shows 54,626,199 shares acquired at formation on 03/01/2023 as background information.